DISEASE MODIFYING THERAPIES WITHDRAWAL IN INACTIVE RELAPSING-REMITTING MULTIPLE SCLEROSIS PATIENTS AGED 55 AND OVER: A MULTICENTRIC, RANDOMIZED, CONTROLLED, OPEN-LABEL CLINICAL TRIAL - TWINS
Latest Information Update: 10 Sep 2025
At a glance
- Drugs Dimethyl fumarate (Primary) ; Diroximel-fumarate (Primary) ; Glatiramer acetate (Primary) ; Interferon beta-1a (Primary) ; Interferon beta-1a (Primary) ; Interferon beta-1a (Primary) ; Interferon beta-1a (Primary) ; Interferon beta-1b (Primary) ; Peginterferon beta-1a (Primary) ; Teriflunomide (Primary)
- Indications Multiple sclerosis
- Focus Therapeutic Use
- Acronyms TWINS
Most Recent Events
- 10 Sep 2025 New trial record